Dr. Reddy's Laboratories Limited — Others, 16-04-2025: Rumour Verification - Regulation 30(11)

Dr. Reddy's Laboratories has addressed speculation regarding a potential acquisition of Sanofi's insulin brand, Lantus, as reported in The Economic Times. While Dr. Reddy's is named as a potential acquirer, the company clarified that there is no material information or event requiring disclosure at this time. This stance aims to maintain transparency while managing market perceptions. Investors may view this as a neutral impact, with limited immediate implications for share price movements, though it highlights ongoing industry activity in the pharmaceutical sector.